CADLCandel Therapeutics, Inc.

Candel Therapeutics remains a clinical-stage biotech with promise but little durable moat today. Its strongest assets are a patent-backed viral immunotherapy platform and emerging clinical data, which could support future differentiation if lead programs continue to advance and reach approval. However, the business lacks true network effects, meaningful customer lock-in, or a defensible cost position, and it operates in a crowded oncology development landscape where scientific success is not rare enough to create structural scarcity. The moat trend is Positive because pipeline maturation and commercialization planning are improving the quality of its intangible assets, but the current moat remains weak and highly contingent on execution, regulatory outcomes, and eventual market adoption.